Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

1.

Gemcitabine and cisplatin combined with regional hyperthermia as second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer.

Tschoep-Lechner KE, Milani V, Berger F, Dieterle N, Abdel-Rahman S, Salat C, Issels RD.

Int J Hyperthermia. 2013;29(1):8-16. doi: 10.3109/02656736.2012.740764. Epub 2012 Dec 17.

PMID:
23245336
[PubMed - indexed for MEDLINE]
2.

Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer.

Kozuch P, Grossbard ML, Barzdins A, Araneo M, Robin A, Frager D, Homel P, Marino J, DeGregorio P, Bruckner HW.

Oncologist. 2001;6(6):488-95.

PMID:
11743211
[PubMed - indexed for MEDLINE]
Free Article
3.

Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma.

Philip PA, Zalupski MM, Vaitkevicius VK, Arlauskas P, Chaplen R, Heilbrun LK, Adsay V, Weaver D, Shields AF.

Cancer. 2001 Aug 1;92(3):569-77.

PMID:
11505401
[PubMed - indexed for MEDLINE]
4.

PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen as second-line therapy in patients with progressive or recurrent pancreatic cancer after gemcitabine-containing chemotherapy.

Reni M, Cereda S, Mazza E, Passoni P, Nicoletti R, Balzano G, Zerbi A, Arcidiacono PG, Staudacher C, Di Carlo V.

Am J Clin Oncol. 2008 Apr;31(2):145-50. doi: 10.1097/COC.0b013e31814688f7.

PMID:
18391598
[PubMed - indexed for MEDLINE]
5.

Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study.

Colucci G, Labianca R, Di Costanzo F, Gebbia V, Cartenì G, Massidda B, Dapretto E, Manzione L, Piazza E, Sannicolò M, Ciaparrone M, Cavanna L, Giuliani F, Maiello E, Testa A, Pederzoli P, Falconi M, Gallo C, Di Maio M, Perrone F; Gruppo Oncologico Italia Meridionale (GOIM); Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente (GISCAD); Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC).

J Clin Oncol. 2010 Apr 1;28(10):1645-51. doi: 10.1200/JCO.2009.25.4433. Epub 2010 Mar 1.

PMID:
20194854
[PubMed - indexed for MEDLINE]
Free Article
6.

Biweekly low-dose sequential gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (GFP): a highly active novel therapy for metastatic adenocarcinoma of the exocrine pancreas.

Araneo M, Bruckner HW, Grossbard ML, Frager D, Homel P, Marino J, DeGregorio P, Mortazabi F, Firoozi K, Jindal K, Kozuch P.

Cancer Invest. 2003;21(4):489-96.

PMID:
14533437
[PubMed - indexed for MEDLINE]
7.

A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer.

Yoo C, Hwang JY, Kim JE, Kim TW, Lee JS, Park DH, Lee SS, Seo DW, Lee SK, Kim MH, Han DJ, Kim SC, Lee JL.

Br J Cancer. 2009 Nov 17;101(10):1658-63. doi: 10.1038/sj.bjc.6605374. Epub 2009 Oct 13.

PMID:
19826418
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

The use of gemcitabine in non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group. Provincial Systemic Treatment Disease Site Group.

Evans WK, Kocha W, Gagliardi A, Eady A, Newman TE.

Cancer Prev Control. 1999 Feb;3(1):84-94.

PMID:
10474757
[PubMed - indexed for MEDLINE]
9.

Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer.

Sandler AB, Nemunaitis J, Denham C, von Pawel J, Cormier Y, Gatzemeier U, Mattson K, Manegold C, Palmer MC, Gregor A, Nguyen B, Niyikiza C, Einhorn LH.

J Clin Oncol. 2000 Jan;18(1):122-30.

PMID:
10623702
[PubMed - indexed for MEDLINE]
10.

Low dose gemcitabine plus cisplatin in a weekly-based regimen as salvage therapy for relapsed breast cancer after taxane-anthracycline-containing regimens.

Sánchez-Escribano Morcuende R, Alés-Martínez JE, Aramburo González PM.

Clin Transl Oncol. 2007 Jul;9(7):459-64.

PMID:
17652060
[PubMed - indexed for MEDLINE]
11.

Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone in patients with advanced non-small cell lung cancer and a performance status of 2: the CAPPA-2 study.

Morabito A, Gebbia V, Di Maio M, Cinieri S, Viganò MG, Bianco R, Barbera S, Cavanna L, De Marinis F, Montesarchio V, Costanzo R, Sandomenico C, Montanino A, Mancuso G, Russo P, Nacci A, Giordano P, Daniele G, Piccirillo MC, Rocco G, Gridelli C, Gallo C, Perrone F.

Lung Cancer. 2013 Jul;81(1):77-83. doi: 10.1016/j.lungcan.2013.04.008. Epub 2013 May 1.

PMID:
23643177
[PubMed - indexed for MEDLINE]
12.

Phase II trial of combined regional hyperthermia and gemcitabine for locally advanced or metastatic pancreatic cancer.

Ishikawa T, Kokura S, Sakamoto N, Ando T, Imamoto E, Hattori T, Oyamada H, Yoshinami N, Sakamoto M, Kitagawa K, Okumura Y, Yoshida N, Kamada K, Katada K, Uchiyama K, Handa O, Takagi T, Yasuda H, Sakagami J, Konishi H, Yagi N, Naito Y, Yoshikawa T.

Int J Hyperthermia. 2012;28(7):597-604. doi: 10.3109/02656736.2012.695428. Epub 2012 Jul 27.

PMID:
22838644
[PubMed - indexed for MEDLINE]
13.

Phase I dose-finding study of biweekly irinotecan in combination with fixed doses of 5-fluorouracil/leucovorin, gemcitabine and cisplatin (G-FLIP) in patients with advanced pancreatic cancer or other solid tumors.

Rachamalla R, Malamud S, Grossbard ML, Mathew S, Dietrich M, Kozuch P.

Anticancer Drugs. 2004 Mar;15(3):211-7.

PMID:
15014353
[PubMed - indexed for MEDLINE]
14.

Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): results of a multicentre randomized phase II trial.

Binder D, Schweisfurth H, Grah C, Schäper C, Temmesfeld-Wollbrück B, Siebert G, Suttorp N, Beinert T.

Cancer Chemother Pharmacol. 2007 Jun;60(1):143-50. Epub 2006 Oct 10.

PMID:
17031643
[PubMed - indexed for MEDLINE]
15.

Fixed dose-rate infusion of gemcitabine in combination with cisplatin and UFT in advanced carcinoma of the pancreas.

Feliu J, Sáenz JG, Jaráiz AR, Castañón C, Cruz M, Fonseca E, Lomas M, Castro J, Jara C, Casado E, León A, Barón MG.

Cancer Chemother Pharmacol. 2006 Oct;58(4):419-26. Epub 2006 Jan 11.

PMID:
16404636
[PubMed - indexed for MEDLINE]
16.

Chemoradiotherapy with concurrent gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine/cisplatin vs chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced pancreatic cancer--a multi-centre randomised phase II study.

Wilkowski R, Boeck S, Ostermaier S, Sauer R, Herbst M, Fietkau R, Flentje M, Miethe S, Boettcher HD, Scholten T, Bruns CJ, Rau HG, Hinke A, Heinemann V.

Br J Cancer. 2009 Dec 1;101(11):1853-9. doi: 10.1038/sj.bjc.6605420. Epub 2009 Nov 10.

PMID:
19904268
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Open-label trial on efficacy and security of treatment with gemcitabine and oral modulation with tegafur and levofolinic acid (GEMTG) in patients with advanced pancreatic cancer.

Pericay Pijaume C, Escudero Emperador P, Bastús Piulats R, Campos Cervera JM, Esquerdo Galiana G, Gallén Castillo M, Alfaro Gamero J, Dotor Navarro E, Pisa Gatell A, Guasch Jordán I, Saigí Grau E; ACROSS group.

Clin Transl Oncol. 2011 Jan;13(1):61-6.

PMID:
21239357
[PubMed - indexed for MEDLINE]
18.

Preclinical and clinical aspects of carboplatin and gemcitabine combined with whole-body hyperthermia for pancreatic adenocarcinoma.

Bakshandeh-Bath A, Stoltz AS, Homann N, Wagner T, Stölting S, Peters SO.

Anticancer Res. 2009 Aug;29(8):3069-77.

PMID:
19661318
[PubMed - indexed for MEDLINE]
Free Article
19.

Gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic cancer: results of a phase II, randomized, noncomparative study.

Richards DA, Kuefler PR, Becerra C, Wilfong LS, Gersh RH, Boehm KA, Zhan F, Asmar L, Myrand SP, Hozak RR, Zhao L, Gill JF, Mullaney BP, Obasaju CK, Nicol SJ.

Invest New Drugs. 2011 Feb;29(1):144-53. doi: 10.1007/s10637-009-9307-8. Epub 2009 Aug 28.

PMID:
19714296
[PubMed - indexed for MEDLINE]
20.

A randomized controlled trial of gemcitabine plus cisplatin versus gemcitabine alone in the treatment of metastatic pancreatic cancer.

Chao Y, Wu CY, Wang JP, Lee RC, Lee WP, Li CP.

Cancer Chemother Pharmacol. 2013 Sep;72(3):637-42. doi: 10.1007/s00280-013-2239-1. Epub 2013 Aug 3.

PMID:
23912692
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk